ROR1 and cancer: Our study aligns with growing evidence from recent literature that SCFAs can significantly shape the immune response by influencing the local gut environment and systemic immune functions, particularly in the context of cancer immunotherapy.[5, 9, 21, 58] Understanding these interactions could be critical for refining CAR T‐cell therapy approaches, particularly for emerging targets like ROR1, where metabolic influences may dictate therapeutic success.